Shahin Lockman publications per year

The chart shows the history of publications by Shahin Lockman between 1997 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Shahin Lockman published across 29 years, from 1997 to 2025, averaging 11.9 papers a year. Output peaked at 31 publications in 2021. 48 of the 344 publications appeared in the last two years.

No. of publications

10 20 30

1997 2025

344 publications in total across all disciplines

View publications per year as a table

Shahin Lockman: publications per year, 1997 to 2025
Year	Publications
1997	1
1998	0
1999	1
2000	3
2001	2
2002	2
2003	4
2004	4
2005	7
2006	3
2007	5
2008	4
2009	4
2010	10
2011	12
2012	15
2013	11
2014	15
2015	8
2016	16
2017	14
2018	27
2019	25
2020	19
2021	31
2022	25
2023	28
2024	31
2025	17
Total	344

Download as CSV

Shahin Lockman publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Shahin Lockman sits on this spectrum.

No. of scientists

50 100 150

62–71 publications 807+

This scientist: 309 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table

Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications	Scientists	This scientist
62–71	9
72–81	23
82–91	40
92–101	72
102–111	86
112–121	108
122–131	150
132–141	160
142–151	159
152–161	189
162–171	166
172–181	181
182–191	188
192–201	187
202–211	178
212–221	158
222–231	168
232–241	159
242–251	160
252–261	148
262–271	116
272–281	125
282–291	115
292–301	111
302–311	95	309
312–321	97
322–331	97
332–341	99
342–351	96
352–361	69
362–371	76
372–381	71
382–391	71
392–401	62
402–411	54
412–421	41
422–431	63
432–441	53
442–451	31
452–461	42
462–471	40
472–481	29
482–491	34
492–501	30
502–511	23
512–521	41
522–531	29
532–541	28
542–551	16
552–561	18
562–571	18
572–581	17
582–591	17
592–601	17
602–611	19
612–621	13
622–631	12
632–641	11
642–651	16
652–661	9
662–671	5
672–681	13
682–691	12
692–701	6
702–711	6
712–721	9
722–731	9
732–741	6
742–751	11
752–761	10
762–771	7
772–781	12
782–791	7
792–801	5
802–806	1
807+	100

Download as CSV

Shahin Lockman D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Shahin Lockman sits on this spectrum.

No. of scientists

50 100 150 200

40–41 D-Index 157+

This scientist: 54 D-Index — 22nd percentile

22% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table

Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index	Scientists	This scientist
40–41	28
42–43	91
44–45	157
46–47	192
48–49	175
50–51	188
52–53	177
54–55	155	54
56–57	194
58–59	201
60–61	197
62–63	201
64–65	173
66–67	167
68–69	172
70–71	199
72–73	184
74–75	133
76–77	163
78–79	127
80–81	121
82–83	125
84–85	121
86–87	102
88–89	96
90–91	75
92–93	72
94–95	74
96–97	66
98–99	68
100–101	49
102–103	60
104–105	54
106–107	36
108–109	23
110–111	52
112–113	41
114–115	34
116–117	25
118–119	28
120–121	11
122–123	20
124–125	27
126–127	19
128–129	20
130–131	16
132–133	17
134–135	14
136–137	15
138–139	9
140–141	11
142–143	9
144–145	9
146–147	7
148–149	7
150–151	7
152–153	5
154–155	8
156	6
157+	96

Download as CSV

Best Publications

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

Unknown

3014
Citations
Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana

R. L. Shapiro;A. Ogwu;D. Kitch;S. Lockman

622
Citations
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.

Ibou Thior;Shahin Lockman;Laura M Smeaton;Roger L Shapiro

600
Citations
Response to Antiretroviral Therapy after a Single, Peripartum Dose of Nevirapine

Shahin Lockman;Roger L Shapiro;Laura M Smeaton;Carolyn Wester

480
Citations
Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein

Shawn M. Sumida;Diana M. Truitt;Angelique A. C. Lemckert;Ronald Vogels

446
Citations
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana

Rebecca Zash;Lewis Holmes;Modiegi Diseko;Denise L. Jacobson

404
Citations
Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis.

Karen H. Costenbader;Karen H. Costenbader;Daniel J. Kim;Jehanna Peerzada;Shahin Lockman

403
Citations
Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana.

Jennifer Y. Chen;Heather J. Ribaudo;Sajini Souda;Natasha Parekh

372
Citations
Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey

Tendani Gaolathe;Kathleen E Wirth;Molly Pretorius Holme;Joseph Makhema

262
Citations
Increased Risk of Preterm Delivery Among HIV-Infected Women Randomized to Protease Versus Nucleoside Reverse Transcriptase Inhibitor-Based HAART During Pregnancy

Kathleen M. Powis;Douglas Kitch;Anthony Ogwu;Michael D. Hughes

252
Citations
Increased Risk of Preterm Delivery Among HIV-Infected Women Randomized to Protease Versus Nucleoside Reverse Transcriptase Inhibitor–Based HAART During Pregnancy

Kathleen M. Powis;Douglas Kitch;Anthony Ogwu;Michael D. Hughes

252
Citations
HIV infection and survival among women with cervical cancer

Scott Dryden-Peterson;Memory Bvochora-Nsingo;Gita Suneja;Jason A. Efstathiou

224
Citations
Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana

Joseph Makhema;Kathleen E Wirth;Molly Pretorius Holme;Tendani Gaolathe

215
Citations
Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.

Rebecca Zash;Denise L. Jacobson;Modiegi Diseko;Gloria Mayondi

204
Citations
Infant Morbidity, Mortality, and Breast Milk Immunologic Profiles among Breast-Feeding HIV-Infected and HIV-Uninfected Women in Botswana

Roger L Shapiro;Shahin Lockman;Soyeon Kim;Laura Smeaton

198
Citations
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

Unknown

195
Citations
Serum Concentrations of Antimycobacterial Drugs in Patients with Pulmonary Tuberculosis in Botswana

Jordan W. Tappero;Williamson Z. Bradford;Williamson Z. Bradford;Williamson Z. Bradford;Tracy B. Agerton;Tracy B. Agerton;Philip Hopewell;Philip Hopewell

191
Citations
Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study

Rebecca Zash;Denise L Jacobson;Modiegi Diseko;Gloria Mayondi

171
Citations
What do the Universal Test and Treat trials tell us about the path to HIV epidemic control

Diane Havlir;Shahin Lockman;Shahin Lockman;Helen Ayles;Joseph Larmarange

154
Citations
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

Shahin Lockman;Shahin Lockman;Sean S Brummel;Lauren Ziemba;Lynda Stranix-Chibanda

145
Citations